Cargando…
Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis
BACKGROUND & AIMS: Ticagrelor has been acknowledged as a new oral antagonist of P2Y12-adenosine diphosphate receptor, as a strategy with more rapid onset as well as more significant platelet inhibition function in acute coronary syndrome (ACS) patients. The clinical benefit of ticagrelor compare...
Autores principales: | Wang, Dong, Yang, Xiao-Hong, Zhang, Ji-Dong, Li, Rui-Bin, Jia, Min, Cui, Xiao-Ran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267904/ https://www.ncbi.nlm.nih.gov/pubmed/30497387 http://dx.doi.org/10.1186/s12872-018-0948-4 |
Ejemplares similares
-
Efficacy and safety outcomes of ticagrelor compared with clopidogrel in elderly Chinese patients with acute coronary syndrome
por: Wang, Huidong, et al.
Publicado: (2016) -
Effects of switching ticagrelor to clopidogrel on cardiovascular outcomes in patients with acute coronary syndrome
por: Liu, Lin, et al.
Publicado: (2018) -
Optimal strategy of switching from clopidogrel to ticagrelor in Chinese acute coronary syndrome patients with complicated coronary artery disease: the switching from clopidogrel to ticagrelor (SHIFT-CACS) study
por: Yao, Ying, et al.
Publicado: (2019) -
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndrome and on Dialysis: A Meta-Analysis
por: Chenna, Venkata Sai Harshabhargav, et al.
Publicado: (2023) -
Comparison of Clinical Outcomes Between Ticagrelor and Clopidogrel in Acute Coronary Syndrome: A Comprehensive Meta-Analysis
por: Sun, Mengyi, et al.
Publicado: (2022)